Play all audios:
ABSTRACT Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicle for RNA therapeutics, partly because of established lipid structure–activity relationships focused on
formulation potency. Yet such knowledge has not extended to LNP immunogenicity. Here we show that the innate and adaptive immune responses elicited by LNPs are linked to their ionizable
lipid chemistry. Specifically, we show that the amine headgroups in ionizable lipids drive LNP immunogenicity by binding to Toll-like receptor 4 and CD1d and by promoting lipid-raft
formation. Immunogenic LNPs favour a type-1 T-helper-cell-biased immune response marked by increases in the immunoglobulins IgG2c and IgG1 and in the pro-inflammatory cytokines tumour
necrosis factor, interferon γ and the interleukins IL-6 and IL-2. Notably, the inflammatory signals originating from these receptors inhibit the production of anti-poly(ethylene glycol) IgM
antibodies, preventing the often-observed loss of efficacy in the LNP-mediated delivery of siRNA and mRNA. Moreover, we identified computational methods for the prediction of the
structure-dependent innate and adaptive responses of LNPs. Our findings may help accelerate the discovery of well-tolerated ionizable lipids suitable for repeated dosing. Access through your
institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature
Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 digital issues and online access to
articles $119.00 per year only $9.92 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which
are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY
OTHERS IONIZATION AND STRUCTURAL PROPERTIES OF MRNA LIPID NANOPARTICLES INFLUENCE EXPRESSION IN INTRAMUSCULAR AND INTRAVASCULAR ADMINISTRATION Article Open access 11 August 2021
IMMUNOGENICITY OF LIPID NANOPARTICLES AND ITS IMPACT ON THE EFFICACY OF MRNA VACCINES AND THERAPEUTICS Article Open access 02 October 2023 POLY(CARBOXYBETAINE) LIPIDS ENHANCE MRNA
THERAPEUTICS EFFICACY AND REDUCE THEIR IMMUNOGENICITY Article 29 May 2025 DATA AVAILABILITY The main data supporting the results in this study are available within the paper and its
Supplementary Information. The raw and analysed datasets and simulation data are available for research purposes from the corresponding author on reasonable request. Source data for the
figures are provided with this paper. REFERENCES * Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. _Nat. Rev. Mater._ 6, 1078–1094 (2021). Article CAS
PubMed PubMed Central Google Scholar * Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. _Nat. Rev.
Drug Discov._ 20, 817–838 (2021). Article CAS PubMed PubMed Central Google Scholar * Hajj, K. A. & Whitehead, K. A. Tools for translation: non-viral materials for therapeutic mRNA
delivery. _Nat. Rev. Mater._ 2, 17056 (2017). Article CAS Google Scholar * Melo, M. et al. Immunogenicity of RNA replicons encoding HIV Env immunogens designed for self-assembly into
nanoparticles. _Mol. Ther._ 27, 2080–2090 (2019). Article CAS PubMed PubMed Central Google Scholar * McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine
candidate induces high neutralizing antibody titers in mice. _Nat. Commun._ 11, 3523 (2020). Article CAS PubMed PubMed Central Google Scholar * Wesselhoeft, R. A. et al. RNA
circularization diminishes immunogenicity and can extend translation duration in vivo. _Mol. Cell_ 74, 508–520.e4 (2019). Article CAS PubMed PubMed Central Google Scholar * Wesselhoeft,
R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. _Nat. Commun._ 9, 2629 (2018). Article PubMed PubMed Central
Google Scholar * Zhang, X. et al. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. _Sci. Adv._ 6, eabc2315 (2020). Article CAS PubMed PubMed Central
Google Scholar * August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. _Nat. Med._ 27, 2224–2233
(2021). Article CAS PubMed PubMed Central Google Scholar * Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. _N. Engl. J. Med._ 385, 493–502 (2021).
Article CAS PubMed Google Scholar * Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. _Nat.
Biotechnol._ 40, 840–854 (2022). Article CAS PubMed Google Scholar * Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. _Nat. Immunol._
23, 532–542 (2022). Article CAS PubMed Google Scholar * Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. _Nature_ 534,
396–401 (2016). Article PubMed Google Scholar * Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. _Nature_ 586, 594–599 (2020). Article CAS
PubMed Google Scholar * Ferraresso, F. et al. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells. _Mol. Pharm._ 19, 2175–2182 (2022).
Article CAS PubMed PubMed Central Google Scholar * Kozma, G. T., Shimizu, T., Ishida, T. & Szebeni, J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune
reactions to PEGylated nano-biopharmaceuticals. _Adv. Drug Deliv. Rev._ 154–155, 163–175 (2020). Article PubMed Google Scholar * Ju, Y. et al. Anti-PEG antibodies boosted in humans by
SARS-CoV-2 lipid nanoparticle mRNA vaccine. _ACS Nano_ 16, 11769–11780 (2022). Article CAS PubMed Google Scholar * Burris, H. A. et al. A phase I multicenter study to assess the safety,
tolerability and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. _J. Clin. Oncol._
37, 2523 (2019). Article Google Scholar * Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. _N. Engl. J. Med._ 383, 2439–2450 (2020). Article CAS
PubMed Google Scholar * Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1
randomized clinical trials. _Vaccine_ 37, 3326–3334 (2019). Article CAS PubMed Google Scholar * Ndeupen, S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in
preclinical vaccine studies is highly inflammatory. _iScience_ 24, 103479 (2021). Article CAS PubMed PubMed Central Google Scholar * Kleinman, M. E. et al. Sequence- and
target-independent angiogenesis suppression by siRNA via TLR3. _Nature_ 452, 591–597 (2008). Article PubMed PubMed Central Google Scholar * Hu, B. et al. Therapeutic siRNA: state of the
art. _Signal Transduct. Target. Ther._ 5, 101 (2020). Article CAS PubMed PubMed Central Google Scholar * Besin, G. et al. Accelerated blood clearance of lipid nanoparticles entails a
biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties. _Immunohorizons_ 3, 282–293 (2019). Article CAS PubMed Google Scholar * Abu Lila, A. S.,
Kiwada, H. & Ishida, T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. _J. Control. Release_ 172, 38–47 (2013). Article CAS PubMed
Google Scholar * Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. _Nat. Commun._ 5, 4277 (2014). Article CAS PubMed Google Scholar
* Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. _Angew. Chem. Int. Ed._ 51, 8529–8533 (2012). Article CAS Google Scholar *
Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. _Nat. Immunol._ 23, 543–555 (2022). Article CAS PubMed PubMed Central Google Scholar *
Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. _Nature_ 596, 410–416 (2021). Article CAS PubMed PubMed Central Google Scholar * de Groot, A. M.
et al. Immunogenicity testing of lipidoids in vitro and in silico: modulating lipidoid-mediated TLR4 activation by nanoparticle design. _Mol. Ther. Nucleic Acids_ 11, 159–169 (2018). Article
PubMed PubMed Central Google Scholar * Pizzuto, M. et al. Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers. _J. Control.
Release_ 247, 182–193 (2017). Article CAS PubMed PubMed Central Google Scholar * Kedmi, R., Ben-Arie, N. & Peer, D. The systemic toxicity of positively charged lipid nanoparticles
and the role of Toll-like receptor 4 in immune activation. _Biomaterials_ 31, 6867–6875 (2010). Article CAS PubMed Google Scholar * Ozinsky, A. et al. The repertoire for pattern
recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. _Proc. Natl Acad. Sci. USA_ 97, 13766–13771 (2000). Article CAS PubMed PubMed
Central Google Scholar * Park, B. S. & Lee, J. O. Recognition of lipopolysaccharide pattern by TLR4 complexes. _Exp. Mol. Med._ 45, e66 (2013). Article PubMed PubMed Central Google
Scholar * Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. _Science_ 282, 2085–2088 (1998). Article CAS PubMed Google Scholar *
Okusawa, T. et al. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by Toll-like receptors 2 and 6. _Infect. Immun._ 72,
1657–1665 (2004). Article PubMed PubMed Central Google Scholar * Irvine, K. L., Hopkins, L. J., Gangloff, M. & Bryant, C. E. The molecular basis for recognition of bacterial ligands
at equine TLR2, TLR1 and TLR6. _Vet. Res._ 44, 50 (2013). Article CAS PubMed PubMed Central Google Scholar * Jin, M. S. et al. Crystal structure of the TLR1-TLR2 heterodimer induced by
binding of a tri-acylated lipopeptide. _Cell_ 130, 1071–1082 (2007). Article CAS PubMed Google Scholar * Ii, M. et al. A novel cyclohexene derivative, ethyl
(6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of
intracellular signaling. _Mol. Pharmacol._ 69, 1288–1295 (2006). Article CAS PubMed Google Scholar * Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the
TLR4–MD-2 complex. _Nature_ 458, 1191–1195 (2009). Article CAS PubMed Google Scholar * Patra, M. C., Kwon, H. K., Batool, M. & Choi, S. Computational insight into the structural
organization of full-length toll-like receptor 4 dimer in a model phospholipid bilayer. _Front. Immunol._ 9, 489 (2018). Article PubMed PubMed Central Google Scholar * Kim, H. M. et al.
Crystal structure of the TLR4–MD-2 complex with bound endotoxin antagonist Eritoran. _Cell_ 130, 906–917 (2007). Article CAS PubMed Google Scholar * Tafazzol, A. & Duan, Y. Key
residues in TLR4–MD2 tetramer formation identified by free energy simulations. _PLoS Comput. Biol._ 15, e1007228 (2019). Article CAS PubMed PubMed Central Google Scholar * Chen, D. et
al. Regulation of protein-ligand binding affinity by hydrogen bond pairing. _Sci. Adv._ 2, e1501240 (2016). Article PubMed PubMed Central Google Scholar * Shimazu, R. et al. MD-2, a
molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. _J. Exp. Med._ 189, 1777–1782 (1999). Article CAS PubMed PubMed Central Google Scholar * Triantafilou,
M., Miyake, K., Golenbock, D. T. & Triantafilou, K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell
activation. _J. Cell Sci._ 115, 2603–2611 (2002). Article CAS PubMed Google Scholar * Wong, S. W. et al. Fatty acids modulate toll-like receptor 4 activation through regulation of
receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. _J. Biol. Chem._ 284, 27384–27392 (2009). Article CAS PubMed PubMed Central Google
Scholar * Lee, J. Y. et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. _J. Lipid Res._ 44, 479–486 (2003).
Article CAS PubMed Google Scholar * Hwang, D. H., Kim, J. A. & Lee, J. Y. Mechanisms for the activation of Toll-like receptor 2/4 by saturated fatty acids and inhibition by
docosahexaenoic acid. _Eur. J. Pharmacol._ 785, 24–35 (2016). Article CAS PubMed PubMed Central Google Scholar * Shaikh, S. R. et al. Oleic and docosahexaenoic acid differentially phase
separate from lipid raft molecules: a comparative NMR, DSC, AFM and detergent extraction study. _Biophys. J._ 87, 1752–1766 (2004). Article CAS PubMed PubMed Central Google Scholar *
Tan, Y., Zanoni, I., Cullen, T. W., Goodman, A. L. & Kagan, J. C. Mechanisms of Toll-like receptor 4 endocytosis reveal a common immune-evasion strategy used by pathogenic and commensal
bacteria. _Immunity_ 43, 909–922 (2015). Article PubMed PubMed Central Google Scholar * Kagan, J. C. et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of
interferon-β. _Nat. Immunol._ 9, 361–368 (2008). Article CAS PubMed PubMed Central Google Scholar * Zanoni, I. et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4.
_Cell_ 147, 868–880 (2011). Article CAS PubMed PubMed Central Google Scholar * Schappe, M. S. & Desai, B. N. Measurement of TLR4 and CD14 receptor endocytosis using flow cytometry.
_Bio Protoc._ 8, e2926 (2018). Article CAS PubMed PubMed Central Google Scholar * Marrink, S. J., Risselada, H. J., Yefimov, S., Tieleman, D. P. & de Vries, A. H. The MARTINI force
field: coarse grained model for biomolecular simulations. _J. Phys. Chem. B_ 111, 7812–7824 (2007). Article CAS PubMed Google Scholar * Monticelli, L. et al. The MARTINI coarse-grained
force field: extension to proteins. _J. Chem. Theory Comput._ 4, 819–834 (2008). Article CAS PubMed Google Scholar * Barnoud, J., Rossi, G., Marrink, S. J. & Monticelli, L.
Hydrophobic compounds reshape membrane domains. _PLoS Comput. Biol._ 10, e1003873 (2014). Article PubMed PubMed Central Google Scholar * Raphael, I., Nalawade, S., Eagar, T. N. &
Forsthuber, T. G. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. _Cytokine_ 74, 5–17 (2015). Article PubMed Google Scholar * Ross, S. H. &
Cantrell, D. A. Signaling and function of interleukin-2 in T lymphocytes. _Annu. Rev. Immunol._ 36, 411–433 (2018). Article PubMed PubMed Central Google Scholar * Saito, H. et al.
Expression and self-regulatory function of cardiac interleukin-6 during endotoxemia. _Am. J. Physiol. Hear. Circ. Physiol._ 279, 2241–2248 (2000). Article Google Scholar * Severgnini, M.
et al. Activation of the STAT pathway in acute lung injury. _Am. J. Physiol. Lung Cell. Mol. Physiol._ 286, 1282–1292 (2004). Article Google Scholar * Godfrey, D. I. & Rossjohn, J. New
ways to turn on NKT cells. _J. Exp. Med._ 208, 1121–1125 (2011). Article PubMed PubMed Central Google Scholar * Singh, A. Eliciting B cell immunity against infectious diseases using
nanovaccines. _Nat. Nanotechnol._ 16, 16–24 (2021). Article CAS PubMed Google Scholar * Lee, M. S. J. et al. B cell-intrinsic MyD88 signaling controls IFN-γ-mediated early IgG2c class
switching in mice in response to a particulate adjuvant. _Eur. J. Immunol._ 49, 1433–1440 (2019). Article CAS PubMed Google Scholar * Vidarsson, G., Dekkers, G. & Rispens, T. IgG
subclasses and allotypes: from structure to effector functions. _Front. Immunol._ 5, 520 (2014). Article PubMed PubMed Central Google Scholar * Stevens, T. L. et al. Regulation of
antibody isotype secretion by subsets of antigen-specific helper T cells. _Nature_ 334, 255–258 (1988). Article CAS PubMed Google Scholar * Snapper, C. M. & Paul, W. E.
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. _Science_ 236, 944–947 (1987). Article CAS PubMed Google Scholar * Nimmerjahn, F. Divergent
immunoglobulin G subclass activity through selective Fc receptor binding. _Science_ 310, 1510–1512 (2005). Article CAS PubMed Google Scholar * Dams, E. T. M. et al. Accelerated blood
clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. _J. Pharmacol. Exp. Ther._ 292, 1071–1079 (2000). CAS PubMed Google Scholar * Ishida, T.
et al. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.
_J. Control. Release_ 105, 305–317 (2005). Article CAS PubMed Google Scholar * Ishida, T. et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible
for rapid elimination of a second dose of PEGylated liposomes. _J. Control. Release_ 112, 15–25 (2006). Article CAS PubMed Google Scholar * Wang, X. Y., Ishida, T. & Kiwada, H.
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. _J. Control. Release_ 119, 236–244 (2007). Article
CAS PubMed Google Scholar * Shimizu, T., Ishida, T. & Kiwada, H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the
accelerated blood clearance phenomenon. _Immunobiology_ 218, 725–732 (2013). Article CAS PubMed Google Scholar * Alabi, C. A. et al. Multiparametric approach for the evaluation of lipid
nanoparticles for siRNA delivery. _Proc. Natl Acad. Sci. USA_ 110, 12881–12886 (2013). Article CAS PubMed PubMed Central Google Scholar * Estapé Senti, M. et al. Anti-PEG antibodies
compromise the integrity of PEGylated lipid-based nanoparticles via complement. _J. Control. Release_ 341, 475–486 (2022). Article PubMed Google Scholar * Sharp, T. H. et al. Insights
into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b. _Proc. Natl Acad. Sci. USA_ 116, 11900–11905 (2019). Article CAS PubMed PubMed Central Google Scholar
* Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. _Science_ 343, 1260–1263 (2014). Article CAS PubMed PubMed Central Google Scholar *
Abed, N. S., Chace, J. H., Fleming, A. L. & Cowdery, J. S. Interferon-γ regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-γ-mediated inhibition
of B cell differentiation. _Cell. Immunol._ 153, 356–366 (1994). Article CAS PubMed Google Scholar * Finkelman, F. D., Katona, I. M., Mosmann, T. R. & Coffman, R. L. IFN-gamma
regulates the isotypes of Ig secreted during in vivo humoral immune responses. _J. Immunol._ 140, 1022–1027 (1988). Article CAS PubMed Google Scholar * Chen, B.-M., Cheng, T.-L. &
Roffler, S. R. Polyethylene glycol immunogenicity: theoretical, clinical and practical aspects of anti-polyethylene glycol antibodies. _ACS Nano._ https://doi.org/10.1021/acsnano.1c05922
(2021). * Mima, Y. et al. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity. _J. Control. Release_ 250, 20–26 (2017). Article CAS PubMed Google Scholar * Hajj, K.
A. et al. A potent branched-tail lipid nanoparticle enables multiplexed mRNA delivery and gene editing in vivo. _Nano Lett._ 20, 5167–5175 (2020). Article CAS PubMed PubMed Central
Google Scholar * Landrum, G. _RDKit: Open-Source Cheminformatics_ (Open-Source Chemoinformatics, 2006); http://rdkit.org * Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated
docking with selective receptor flexibility. _J. Comput. Chem._ 30, 2785–2791 (2009). Article CAS PubMed PubMed Central Google Scholar * Berman, H. M. et al. The Protein Data Bank.
_Nucleic Acids Res._ 28, 235–242 (2000). Article CAS PubMed PubMed Central Google Scholar * Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with
a new scoring function, efficient optimization and multithreading. _J. Comput. Chem._ 31, 455–461 (2010). Article CAS PubMed PubMed Central Google Scholar * Schrödinger, L. _The PyMOL
Molecular Graphics System_, Version 2.5. (Schrödinger LLC, 2021); http://www.pymol.org/pymol * Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams
for drug discovery. _J. Chem. Inf. Model._ 51, 2778–2786 (2011). Article CAS PubMed Google Scholar * Lindahl, E., Abraham, M. J, Hess, B. & van der Spoel, D. GROMACS 2020.2 Source
code. _Zenodo_ https://doi.org/10.5281/zenodo.3773801 (2020). * Wassenaar, T. A., Ingólfsson, H. I., Böckmann, R. A., Tieleman, D. P. & Marrink, S. J. Computational lipidomics with
insane: a versatile tool for generating custom membranes for molecular simulations. _J. Chem. Theory Comput._ 11, 2144–2155 (2015). Article CAS PubMed Google Scholar * Humphrey, W.,
Dalke, A. & Schulten, K. VMD: visual molecular dynamics. _J. Mol. Graph._ 14, 33–38 (1996). Article CAS PubMed Google Scholar * Reitman, S. & Frankel, S. A colorimetric method
for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. _Am. J. Clin. Pathol._ 28, 56–63 (1957). Article CAS PubMed Google Scholar Download references
ACKNOWLEDGEMENTS Funding for this research was provided by the NIH (grant number DP2-HD098860), the Wadhwani Foundation, and generous support from Jon Saxe and Myrna Marshall. M.L.A.
discloses support for the research described in this study from the NSF Graduate Research Fellowship Program (award number DGE1745016). J.R.M. discloses support for the research described in
this study from an NIH F32 fellowship (number 1F32EB029345). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA,
USA Namit Chaudhary, Lisa N. Kasiewicz, Alexandra N. Newby, Mariah L. Arral, Saigopalakrishna S. Yerneni, Jilian R. Melamed, Samuel T. LoPresti, Katherine C. Fein & Kathryn A. Whitehead
* Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, USA Daria M. Strelkova Petersen & Kathryn A. Whitehead * Department of Biosciences and Bioengineering,
Indian Institute of Technology Bombay, Mumbai, India Sushant Kumar & Rahul Purwar Authors * Namit Chaudhary View author publications You can also search for this author inPubMed Google
Scholar * Lisa N. Kasiewicz View author publications You can also search for this author inPubMed Google Scholar * Alexandra N. Newby View author publications You can also search for this
author inPubMed Google Scholar * Mariah L. Arral View author publications You can also search for this author inPubMed Google Scholar * Saigopalakrishna S. Yerneni View author publications
You can also search for this author inPubMed Google Scholar * Jilian R. Melamed View author publications You can also search for this author inPubMed Google Scholar * Samuel T. LoPresti View
author publications You can also search for this author inPubMed Google Scholar * Katherine C. Fein View author publications You can also search for this author inPubMed Google Scholar *
Daria M. Strelkova Petersen View author publications You can also search for this author inPubMed Google Scholar * Sushant Kumar View author publications You can also search for this author
inPubMed Google Scholar * Rahul Purwar View author publications You can also search for this author inPubMed Google Scholar * Kathryn A. Whitehead View author publications You can also
search for this author inPubMed Google Scholar CONTRIBUTIONS N.C., L.N.K., R.P. and K.A.W designed the research. N.C., L.N.K., A.N.N., M.L.A., S.S.Y, J.R.M., S.T.L., K.C.F., D.M.S. P. and
S.K. performed research. N.C., L.N.K., A.N.N., M.L.A., S.S.Y., J.R.M., S.T.L. and S.K. analysed data. K.A.W. secured funding and provided oversight of the project. N.C. and K.A.W. wrote the
paper. CORRESPONDING AUTHOR Correspondence to Kathryn A. Whitehead. ETHICS DECLARATIONS COMPETING INTERESTS K.A.W. is an inventor on US patents 9,227,917 (2016) and 9,439,968 (2016) related
to the materials described here, and is a consultant for several companies dealing with non-viral RNA delivery. PEER REVIEW PEER REVIEW INFORMATION _Nature Biomedical Engineering_ thanks Dan
Peer and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations. EXTENDED DATA EXTENDED DATA FIG. 1 IMMUNE RESPONSE OF TAIL GROUPS VARIES WITH SAMPLING TIME, TYPE OF SAMPLE, AND
MEASURED ANALYTE. Mice were dosed twice, 30 days apart, with 1 mg/kg siGFP-LNPs. Proinflammatory cytokine levels were measured in serum (A, B) four hours after each dose, (C-F) two and seven
days after the second dose, and (G-J) in stimulated splenocyte supernatant seven days after the second dose (n = 3–4). Error bars represent s.e.m. Significance was determined according to
according to two-way ANOVA with Tukey’s post-hoc analysis. Source data EXTENDED DATA FIG. 2 313 LNPS ELICIT HIGHER LEVELS OF INFLAMMATORY CYTOKINES IN STIMULATED SPLENOCYTES. Mice were dosed
twice, 30 days apart, with 1 mg/kg siGFP-LNPs. Spleens were collected seven days after the second LNP dose. Isolated splenocytes were stimulated with either PMA/ionomycin or LPS for 24
hours, and (A) TNFα, (B) IL-6, (C) IFNγ, and (D) IL-2 were measured from cell culture supernatant. PBS was used as a negative control (n = 3–4). Error bars represent s.e.m. Significance was
determined according to two-way ANOVA with Tukey’s post-hoc analysis. Source data EXTENDED DATA FIG. 3 CD1D AND TLR4 BLOCKADE INCREASES ANTI-PEG RESPONSES FOR 306OI10. Mice were injected
with 306Oi10 LNPs along with CD1d and TLR4 inhibitors and corresponding isotype and solvent controls 30 days apart, and (A) anti-PEG IgM and (B) anti-PEG IgG levels were measured weekly (n =
5). Significance was determined according to two-way ANOVA with Tukey’s post-hoc analysis. Source data EXTENDED DATA FIG. 4 SM-102 ELICITS SIMILAR EFFICACY AND IMMUNE RESPONSE AS 306OI10.
(A) Mice were IV-injected twice with SM-102, 306Oi10, or 304Oi10 LNPs containing anti-Factor VII siRNA at a dose of 0.5 mg/kg one month apart, and Factor VII levels were measured two days
after each injection relative to PBS negative control (n = 3). In separate experiments, mice were IV-injected twice with LNPs containing anti-GFP siRNA one month apart at a dose of 1 mg/kg.
Blood was collected four hours after each dose, and (B) TNFα and (C) IL-6 levels were measured using ELISA. Two and seven days after the second dose, counts of (D) germinal center cells, (E)
plasma cells, (F) and memory B cells were assessed via flow cytometry, and (G) TNFα and (H) IL-6 levels were measured using ELISA (n = 4). Mice were IV-injected twice with LNPs containing
anti-GFP siRNA one month apart at a dose of 1 mg/kg. Blood was collected weekly for two months, and (I) anti-PEG IgM and (J) anti-PEG IgG levels were measured using ELISA (n = 4). Error bars
represent s.e.m. Significance was determined according to two-way ANOVA with Šidák’s post-hoc analysis (A-H) or Tukey’s post-hoc analysis (I, J). Source data SUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Supplementary Figs. 1–13 and Table 1. REPORTING SUMMARY SOURCE DATA SOURCE DATA FIGS. 1–6 Statistical source data. SOURCE DATA EXTENDED DATA FIGS. 1–4 Statistical
source data. RIGHTS AND PERMISSIONS Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s)
or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Reprints
and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Chaudhary, N., Kasiewicz, L.N., Newby, A.N. _et al._ Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles
by binding to the receptors TLR4 and CD1d. _Nat. Biomed. Eng_ 8, 1483–1498 (2024). https://doi.org/10.1038/s41551-024-01256-w Download citation * Received: 04 November 2022 * Accepted: 05
September 2024 * Published: 03 October 2024 * Issue Date: November 2024 * DOI: https://doi.org/10.1038/s41551-024-01256-w SHARE THIS ARTICLE Anyone you share the following link with will be
able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing
initiative